相似文献
1
Plasmodium falciparum resistance to piperaquine driven by PfCRT.
Lancet Infect Dis. 2019 Nov;19(11):1168-1169. doi: 10.1016/S1473-3099(19)30543-2.
2
Multigenic architecture of piperaquine resistance trait in Plasmodium falciparum.
Lancet Infect Dis. 2020 Jan;20(1):26-27. doi: 10.1016/S1473-3099(19)30689-9.
3
Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine.
Nat Commun. 2018 Aug 17;9(1):3314. doi: 10.1038/s41467-018-05652-0.
4
Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
Malar J. 2019 Jan 17;18(1):10. doi: 10.1186/s12936-019-2640-2.
5
Combinatorial Genetic Modeling of pfcrt-Mediated Drug Resistance Evolution in Plasmodium falciparum.
Mol Biol Evol. 2016 Jun;33(6):1554-70. doi: 10.1093/molbev/msw037. Epub 2016 Feb 22.
6
Polymorphisms of pfcrt, pfmdr1, and K13-propeller genes in imported falciparum malaria isolates from Africa in Guizhou province, China.
BMC Infect Dis. 2020 Jul 16;20(1):513. doi: 10.1186/s12879-020-05228-8.
7
[In vitro sensitivity of Plasmodium falciparum isolates from China-Myanmar border region to chloroquine, piperaquine and pyronaridine].
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2012 Feb 29;30(1):41-4.
8
Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia.
Am J Trop Med Hyg. 2016 Dec 7;95(6):1228-1238. doi: 10.4269/ajtmh.16-0234. Epub 2016 Oct 17.
9
New genetic marker for piperaquine resistance in Plasmodium falciparum.
Lancet Infect Dis. 2017 Feb;17(2):119-121. doi: 10.1016/S1473-3099(16)30414-5. Epub 2016 Nov 3.
10
Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia.
Lancet Infect Dis. 2019 Sep;19(9):916-917. doi: 10.1016/S1473-3099(19)30394-9. Epub 2019 Jul 22.
引用本文的文献
1
The plasmepsin-piperaquine paradox persists in Plasmodium falciparum.
PLoS Pathog. 2025 Jul 28;21(7):e1012779. doi: 10.1371/journal.ppat.1012779. eCollection 2025 Jul.
2
Plasmodiumfalciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity.
Cell Chem Biol. 2025 Jul 17;32(7):926-941.e23. doi: 10.1016/j.chembiol.2025.06.003. Epub 2025 Jul 7.
3
Slowing the spread of treatment failure to artemisinin-based combination therapies in Uganda.
medRxiv. 2025 May 18:2025.05.15.25327701. doi: 10.1101/2025.05.15.25327701.
4
Decreased dihydroartemisinin-piperaquine protection against recurrent malaria associated with Plasmodium falciparum plasmepsin 3 copy number variation in Africa.
Nat Commun. 2025 Mar 18;16(1):2680. doi: 10.1038/s41467-025-57726-5.
5
Plasmodium falciparum African PfCRT Mutant Isoforms Conducive to Piperaquine Resistance Are Infrequent and Impart a Major Fitness Cost.
J Infect Dis. 2025 Jun 2;231(5):e976-e985. doi: 10.1093/infdis/jiae617.
6
A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants.
PLoS Pathog. 2024 Oct 29;20(10):e1012627. doi: 10.1371/journal.ppat.1012627. eCollection 2024 Oct.
7
A genetic cross reveals the contributions of and to piperaquine drug resistance.
mBio. 2024 Jul 17;15(7):e0080524. doi: 10.1128/mbio.00805-24. Epub 2024 Jun 24.
8
Combating antimicrobial resistance in malaria, HIV and tuberculosis.
Nat Rev Drug Discov. 2024 Jun;23(6):461-479. doi: 10.1038/s41573-024-00933-4. Epub 2024 May 15.
9
Incomplete growth inhibition following piperaquine treatment translates into increased parasite viability in the parasite reduction ratio assay.
Front Cell Infect Microbiol. 2024 Apr 30;14:1396786. doi: 10.3389/fcimb.2024.1396786. eCollection 2024.
10
Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum.
Nat Commun. 2024 Feb 15;15(1):1390. doi: 10.1038/s41467-024-45547-x.
本文引用的文献
1
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.
Lancet Infect Dis. 2019 Sep;19(9):952-961. doi: 10.1016/S1473-3099(19)30391-3. Epub 2019 Jul 22.
2
Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.
Lancet Infect Dis. 2019 Sep;19(9):943-951. doi: 10.1016/S1473-3099(19)30392-5. Epub 2019 Jul 22.
3
Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine.
Nat Commun. 2018 Aug 17;9(1):3314. doi: 10.1038/s41467-018-05652-0.
4
A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.
Lancet Infect Dis. 2017 Feb;17(2):174-183. doi: 10.1016/S1473-3099(16)30415-7. Epub 2016 Nov 3.
5
Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study.
Lancet Infect Dis. 2017 Feb;17(2):164-173. doi: 10.1016/S1473-3099(16)30409-1. Epub 2016 Nov 3.
Zotero 插件